# China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD

> **NCT06666413** · PHASE4 · RECRUITING · sponsor: **Genzyme, a Sanofi Company** · enrollment: 13 (estimated)

## Conditions studied

- Glycogen Storage Disease Type II
- Pompe's Disease

## Interventions

- **DRUG:** Avalglucosidase alfa

## Key facts

- **NCT ID:** NCT06666413
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2028-05-02
- **Final completion:** 2028-05-02
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666413, "China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06666413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*